Takeda Pharmaceuticals completed its acquisition of Shire Pharmaceuticals

completed Shire's acquisition for 46 billion pounds, just eight months after the deal was announced and closed.The merger creates a global, value-based, research and development-oriented biopharmaceutical leader, headquartered in Japan, making the 237-year-old pharmaceutical company one of the world's top 10 pharmaceutical companies.Shares have fallen about 20 per cent since the deal was first acknowledged in April, but rose 2 per cent on Tuesday after the deal was closed in a statement.Completed months ahead of schedule, the new pharmaceutical giant will focus on four therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases and plasma-derived therapies.Takeda announced its acquisition of the company in May 2018 after its merger proposal was previously rejected four times by Hill, and then at least 88 percent of Takeda shareholders voted in favour of the proposal in December 2018."We are pleased that this acquisition was approved by the overwhelming majority of shareholders at the Takeda Special General Meeting on December 5, 2018," said Christopher Weber, President and CEO of Takeda. We are also pleased to be able to complete the acquisition a few months earlier than expected, through the hard work of our respective organizations and the successful receipt of regulatory approvals. Weemployees, partners and shareholders for their support throughout the process. This marks an important moment in Takeda's history and is an exciting step as we accelerate our transformation to deliver highly innovative drugs to patients around the world, expanding their scale and geographic reach. " (Compiled by this web)